Pharmacokinetics and Safety of Radiprodil in Hepatic Impairment

Phase 1, open-label trial of radiprodil in GRIN-related neurodevelopmental disorder, tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) (5 arms), sponsored by GRIN Therapeutics, Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration of Radiprodil, Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity of Radiprodil and 6 more. Started Mar 2026; status: recruiting.